Medical insurance price of zanubrutinib

Zanubrutinib (Zanubrutinib) is used to treat mantle cell lymphoma (MCL) in adults who have received at least one cancer treatment. enströ macroglobulinemia (WM), also used to treat marginal zone lymphoma (MZL) that has relapsed or failed to respond to treatment (refractory) in patients who have received at least one prior treatment (such as anti-CD20-based therapy). This drug is also used to treat chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Zanubrutinib is an antineoplastic drug (cancer drug). It interferes with the growth of cancer cells, which are eventually destroyed by the body.

Zanubrutinib is a small molecule inhibitor of Bruton tyrosine kinase (BTK). Zanubrutinib forms covalent bonds with cysteine u200bu200bresidues in the active site of BTK, resulting in inhibition of BTK activity. BTK is a signaling molecule of the B cell antigen receptor (BCR) and cytokine receptor pathways. InB cells, BTK signaling leads to the activation of pathways necessary for B cell proliferation, trafficking, chemotaxis, and adhesion. In non-clinical studies, zanubrutinib inhibited malignant B cell proliferation and reduced tumor growth.

ZanubrutinibThe original drug has been launched in China and has been included in the medical insurance, but it is only reimbursed for patients who meet the indications. SpecificationsThe price of 80mg*64 pills per box may be around 6,000 yuan. This drug can only be purchased with a doctor’s prescription. Patients who do not meet the reimbursement conditions can only purchase it at their own expense. The reimbursement ratio is different in different regions, and the price after reimbursement may also be different. The original drug of zanubrutinib marketed overseas is relatively expensive, and there are currently no generic drugs of zanubrutinib on the market.